Roche ocrelizumab subcutaneous injection
OCREVUS subcutaneous injection was comparable to intravenous (IV) infusion in providing near-complete suppression of multiple sclerosis brain lesions over 24 weeks, Phase III study data shows.
https://www.europeanpharmaceuticalre...breaking-data/
OCREVUS subcutaneous injection was comparable to intravenous (IV) infusion in providing near-complete suppression of multiple sclerosis brain lesions over 24 weeks, Phase III study data shows.
https://www.europeanpharmaceuticalre...breaking-data/